Construction method of extracellular vesicle long-chain RNA library
Through random primer reverse transcription and CRISPR/Cas9-sgRNA treatment, the problem of long-chain RNA preparation in extracellular vesicles was solved, and a high-quality long-chain RNA library was obtained, which promoted its application in disease diagnosis and treatment markers.
Patent Information
- Application Number
- CN202310660589.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
The existing technology is difficult to effectively prepare and study long-chain RNA in extracellular vesicles. It is mainly due to its fragmentation and low yield, which leads to the inability to use the common RNAs-seq method, which limits the research on the species and abundance of long-chain RNA and its role. Development of markers for diagnosis and treatment of diseases.
Random primer reverse transcription combined with CRISPR/Cas9-sgRNA treatment was used to remove ribosomal RNA through pre-amplification, purification and re-amplification to obtain extracellular vesicle long-chain RNA library.
High-quality, repeatable extracellular vesicle long-chain RNA library preparation has been achieved, which has improved the research ability of long-chain RNA species and abundance, and enhanced its potential as a marker of disease diagnosis and treatment.
Smart Images

Figure BDA0004269024550000131 
Figure BDA0004269024550000141 
Figure BDA0004269024550000151
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and more specifically, the present invention relates to a method for preparing an extracellular vesicle long-chain RNA library. Background Art
[0002] Extracellular vesicles (EVs) are membrane structures released by cells into the extracellular space. They vary in size (from 40 nanometers to several micrometers) and are wrapped by a phospholipid bilayer membrane. Recent studies have shown that EVs can be used as carriers for transferring bioactive molecules, transporting proteins, lipids, DNA and RNA, and completing information exchange between cells. At the same time, they are also involved in a variety of physiological and pathological processes, such as inflammatory responses, immune disorders, neurological diseases and cancer. Therefore, this research field has received increasing attention.
[0003] The extracellular vesicles released by tumor cells contain some contents that are unique to tumors, such as specifically expressed surface proteins, tumor-specific mutated DNA fragments, and unique highly expressed RNA fragments. More and more studies have shown that tumor-derived extracellular vesicles can circulate in the blood and affect the function and metabolism of their receptor cells, creating a new microenvironment suitable for tumor cell growth, thereby promoting the metastasis of tumor cells. Therefore, extracellular vesicles in the blood can be used as a new type of molecular marker for tumor identification. Information such as their quantity, size, and type, as well as biological macromolecules such as proteins, lipids, DNA, and RNA contained therein can all be used to identify related tumors. Among them, the large number of RNA molecules are rich in information and can truly reflect the physiological state of tumor cells. They are an excellent tumor identification marker.
[0004] The composition and size of RNA in extracellular vesicles are quite different from those in cells. The size of intracellular RNA is distributed between 400-12,000nt, while the RNA in extracellular vesicles is less than 500nt, mainly some long RNA fragments and different types of small RNA, including mRNA fragments, lncRNA fragments, miRNA, piRNA, rRNA fragments, tRNA fragments and Y-RNA fragments, which leads to technical bottlenecks in the preparation of its long-chain library.
[0005] High-throughput sequencing is an efficient method for studying the composition and abundance of RNA molecules, and can be used to quickly screen RNA markers for tumor identification. Thanks to the maturity of small RNA sequencing technology, the types and expressions of small RNAs in extracellular vesicles have become well known, and are widely used in early screening, prognosis, and recurrence detection of diseases such as tumors. Compared with small RNAs, researchers know little about long-chain RNAs in extracellular vesicles. One of the key factors is the particularity of long-chain RNA molecules in extracellular vesicles, which makes the currently commonly used RNAs-seq methods unsuitable: extracellular vesicle long-chain RNAs are generally fragmented RNAs, which are relatively short and do not have poly (A) tails, so it is impossible to use oligo-dT reverse transcription-based library preparation; the yield of extracellular vesicle RNA is relatively low, and on average only about 2-5ng of extracellular vesicle RNA can be obtained from 1ml of plasma, so most methods based on random primer reverse transcription cannot be used due to insufficient sensitivity.
[0006] Therefore, the current lack of methods for preparing extracellular vesicle long-chain RNA libraries has greatly limited the research on the types and abundance of extracellular vesicle long-chain RNAs, and also greatly hindered the development of using extracellular vesicle long-chain RNA information as a disease diagnosis and treatment marker. Summary of the invention
[0007] The object of the present invention is to provide a method for preparing an extracellular vesicle long-chain RNA library, which uses extracellular vesicle RNA as a template, uses random primers for reverse transcription, and obtains an extracellular vesicle long-chain RNA library by a "pre-amplification-purification-reamplification" method combined with Cas9-sgRNA treatment. The present invention also provides the prepared extracellular vesicle long-chain RNA library and its application.
[0008] In a first aspect of the present invention, a method for preparing an extracellular vesicle (EV) long-chain RNA library is provided, comprising:
[0009] i) providing extracellular vesicle RNA, performing RNA fragmentation, and obtaining fragmentation products;
[0010] ii) reverse transcription using random primers to obtain reverse transcription products;
[0011] iii) performing a first amplification (pre-amplification) on the reverse transcription product and purifying it to obtain cDNA;
[0012] iv) Removal of ribosomal RNA (rRNA) using sgRNA targeting ribosomal RNA (rRNA) by CRISPR / Cas method;
[0013] v) Perform a second amplification and purify the cDNA to obtain an extracellular vesicle long-chain RNA library.
[0014] In one or more embodiments, the long chain is a nucleic acid chain with a length of 80-6000 nt, preferably 100-1000 nt.
[0015] In one or more embodiments, the Cas is Cas9.
[0016] In one or more embodiments, the extracellular vesicle RNA is RNA extracted from extracellular vesicles; preferably, the extracellular vesicles are derived from cells, tissues and body fluids; more preferably, the extracellular vesicles are derived from cell supernatant, serum, plasma, urine, cerebrospinal fluid, saliva, nasal secretions, alveolar lavage fluid, milk, synovial fluid, semen, uterine fluid, bile, lymph fluid, feces, adipose tissue, brain tissue, amniotic fluid, and embryo culture fluid.
[0017] In one or more embodiments, step i) further comprises: removing DNA from the extracellular vesicle RNA.
[0018] In one or more embodiments, the removal of DNA in the extracellular vesicle RNA includes: removing DNA in the extracellular vesicle RNA by DNase treatment.
[0019] In one or more embodiments, the DNA enzyme includes: DNase I, Turbo DNase.
[0020] In one or more embodiments, 0.25-0.50 units of DNase are used for 1 ng of extracellular vesicle RNA.
[0021] In one or more embodiments, 0.28-0.45 units of DNA enzyme are used for 1 ng of extracellular vesicle RNA, such as 0.30, 0.32, 0.33, 0.35, 0.38, 0.40, or 0.42 units of DNA enzyme.
[0022] In one or more embodiments, the temperature of the DNA enzyme treatment is 37±5°C; preferably 37±3°C or 37±2°C or 37±1°C.
[0023] In one or more embodiments, the DNase treatment time is 30±15 minutes; preferably 30±10 minutes; more preferably 30±5 minutes.
[0024] In one or more embodiments, in the step i), the RNA fragmentation includes: RNA shearing treatment by chemical method and / or enzymatic digestion method; preferably, after RNA fragmentation, the RNA fragment size is 80 to 300 nt; more preferably, RNA is fragmented in a reverse transcription buffer containing magnesium ions.
[0025] In one or more embodiments, the fragmentation is performed at an elevated temperature.
[0026] In one or more embodiments, the fragmentation temperature is 84±20°C; preferably 84±15°C, 84±10°C or 84±5°C.
[0027] In one or more embodiments, the fragmentation time is 2±1 minutes; preferably, 2±0.5 minutes; and more preferably, 2±0.3 minutes.
[0028] In one or more embodiments, the concentration of magnesium ions is 1-5 mM.
[0029] In one or more embodiments, the reverse transcription buffer is Tris-HCl, pH 8.3 25°C.
[0030] In one or more embodiments, the step ii) comprises: reverse transcription using random primers and adding a 3' adapter sequence, and template switching and adding a 5' adapter sequence.
[0031] In one or more embodiments, the random primer carries a sequence compatible with an Illumina sequencing adapter. More preferably, the Illumina sequencing adapter sequence is as shown in SEQ ID NO: 1 or 2.
[0032] In one or more embodiments, the template switching is performed by using a template switching oligonucleotide to add a 5' linker sequence to the end of the cDNA; more preferably, the template switching oligonucleotide sequence is as shown in SEQ ID NO: 3 or 29.
[0033] In one or more embodiments, in step iv), the sgRNA includes sgRNAs selected from the nucleotide sequences shown in SEQ ID NOs: 30 to 108 (e.g., containing at least 20, 30, 40, 50, 60, 70, or 80).
[0034] In one or more embodiments, the purification method described in step iii) and step v) is purification using magnetic beads; preferably, the cDNA fragment size obtained after purification using magnetic beads is 200-500 bp.
[0035] In one or more embodiments, the amplification in step iii) and step v) is PCR amplification; preferably, the PCR amplification in step iii) is a PCR amplification with a low cycle number (5 to 7 cycles), and the PCR amplification in step v) is a PCR amplification with a high cycle number (7 to 10 cycles).
[0036] In one or more embodiments, in step iii), when the first amplification is performed, amplification is performed using primers shown in SEQ ID NOs: 5 and 6, or SEQ ID NOs: 7 and 8, and / or, in step v), when the second amplification is performed, amplification is performed using primers shown in SEQ ID NOs: 7 and 8, or SEQ ID NOs: 27 and 28.
[0037] In one or more embodiments, the preparation method further comprises: performing quality inspection and / or sequencing on the obtained extracellular vesicle long-chain RNA library.
[0038] In one or more embodiments, the quality control includes: determination of cDNA library concentration, detection of library size distribution and / or fluorescence quantitative PCR analysis.
[0039] In the second aspect of the present invention, an extracellular vesicle long-chain RNA library is provided, which is prepared by the method for preparing the extracellular vesicle long-chain RNA library described in the present invention.
[0040] In a third aspect of the present invention, the application of the method for preparing the extracellular vesicle long-chain RNA library of the present invention is provided, including (but not limited to) for:
[0041] Perform sequencing analysis or sequence comparison;
[0042] Conduct analysis of gene structure, expression or regulation;
[0043] Screening or analysis of functional genes;
[0044] Screening or analyzing disease genes (disease-causing genes);
[0045] Monitoring or analysing IVF embryo quality or sperm quality; or
[0046] Analysis of gene abundance.
[0047] In one or more embodiments, the disease includes (but is not limited to): tumor, preeclampsia, Parkinson's disease.
[0048] In one or more embodiments, the screening or analysis includes screening or analysis in the absence of disease, early stage, middle stage, late stage of disease, or prognosis.
[0049] In a fourth aspect of the present invention, a method for removing ribosomal RNA from a cDNA product (preferably a pre-amplification product) of extracellular vesicle RNA is provided, comprising: using an sgRNA targeting ribosomal RNA and removing the ribosomal RNA by a CRISPR / Cas method; preferably, the sgRNA comprises an sgRNA selected from a nucleotide sequence as shown in SEQ ID NO: 30 to 108 (e.g., containing at least 20, 30, 40, 50, 60, 70, 80 sequences).
[0050] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 , basic characteristics of exosomes and exosomal RNA. a. Electron microscopy results showed that exosomes were in the shape of a round cake with a depression in the middle, and the size was about 100nm. b. NTA results showed that the size of exosomes was between 50-200nm, with a peak at about 120nm. c. Analysis of the length of exosomal RNA.
[0052] Figure 2 , Determination of the optimal DNase I concentration for the removal of residual DNA in exosome RNA. a. Experimental process. Six different internal reference DNAs were mixed in a certain proportion to obtain a DNA mixture, which was mixed with EV RNA to obtain a test sample. After the test sample was treated with different concentrations of DNase I, the content of the internal reference DNA was detected by qPCR. By comparing the difference between treatment and no treatment, and between different concentrations of DNase I treatment, the optimal concentration of DNase treatment can be obtained. b. The bar graph shows the results of the treatment in a.
[0053] Figure 3 , the impact of different amplification strategies on the library. a. Direct amplification strategy of reverse transcription products. b. Reverse transcription products are purified by magnetic beads before amplification. c. Low-cycle pre-amplification of reverse transcription products followed by magnetic bead purification and then amplification. d. Different amplification strategies yield different library qualities. The low-cycle amplification-purification-re-amplification strategy of reverse transcription products can greatly remove byproducts and enrich the effective library.
[0054] Figure 4 , Selection of different amplification primer combinations and template switching sequences. a, Schematic diagram of two amplification primer combination strategies. b, Effects of different amplification primer combinations and template switching sequences on library quality.
[0055] Figure 5 , sgRNA preparation and quality inspection. a. Agarose gel electrophoresis to confirm the size and purity of some DNA templates. b. RNA capillary electrophoresis to confirm the size and purity of some sgRNAs.
[0056] Figure 6 , Cas-sgRNA removal of ribosomal RNA effect. a. The proportion of effective libraries, cell ribosomal RNA libraries and mitochondrial ribosomal RNA libraries in the plasma extracellular vesicle long-chain RNA before and after treatment with the Cas9-sgRNA complex. b. The proportion of effective libraries, cell ribosomal RNA libraries and mitochondrial ribosomal RNA libraries in the serum extracellular vesicle long-chain RNA before and after treatment with the Cas9-sgRNA complex.
[0057] Figure 7 , Method sensitivity and repeatability evaluation. a. Use 100pg to 2ng of extracellular vesicle RNA to prepare long-chain RNA libraries and analyze the number of genes detected in them. b. Correlation analysis between repeated samples.
[0058] Figure 8 , characteristics of long-chain RNA in plasma extracellular vesicles. a. Ratio of ribosomal RNA products in sequencing analysis library. b. Number of genes detected. c. Correlation analysis between different samples. d. Cluster analysis of the top 10,000 genes expressed in different samples. DETAILED DESCRIPTION
[0059] the term
[0060] The "RNA library" described herein refers to a library containing RNA generated by reverse transcription using an RNA template. The "extracellular vesicle long-chain RNA library" refers to a library containing long-chain RNA generated by reverse transcription using a long-chain RNA derived from an extracellular vesicle as a template.
[0061] The "pre-amplification" and "first amplification" described herein can be used interchangeably. Similarly, the "re-amplification" and "second amplification" can be used interchangeably.
[0062] The "amplification", "pre-amplification" or "re-amplification" mentioned herein, unless otherwise specified, refers to amplification by the polymerase chain reaction (PCR) method.
[0063] Herein, the terms “extracellular vesicle”, “Extracellular Vesicle” and “EV” are used interchangeably.
[0064] Preparation method of extracellular vesicle long-chain RNA library
[0065] Extracellular vesicles is a general term, which mainly includes exosomes, microvesicles (MV), apoptotic bodies and large oncosomes. In general, extracellular vesicles are spherical membrane vesicles with a diameter of 40 nanometers to 10 micrometers. Under transmission electron microscopy, they appear as cup-shaped structures due to fixed damage.
[0066] Unlike the intracellular RNA, which is distributed between 400-12,000 nt in size, the RNA in extracellular vesicles is less than 500 nt, mainly some long RNA fragments and different types of small RNAs, including mRNA fragments, lncRNA fragments, miRNA, piRNA, rRNA fragments, tRNA fragments and Y-RNA fragments, which is an obstacle to the preparation of its long-chain library. The inventors also found that the content of ribosomal RNA (rRNA) fragments in the RNA of extracellular vesicles is very high, accounting for 50-90% of all small RNAs; and this type of rRNA greatly affects the purity of the RNA library of extracellular vesicles, and it is necessary to find an effective method to separate it.
[0067] After in-depth research, the inventors have provided a method for preparing an extracellular vesicle long-chain RNA library based on the molecular characteristics of extracellular vesicle long-chain RNA. The advantage of this method is that according to the characteristics of extracellular vesicle long-chain RNA without poly (A) and fragmentation, high-quality and reproducible extracellular vesicle long-chain RNA expression information can be obtained using 100pg or more of extracellular vesicle RNA.
[0068] In a preferred embodiment, the method for preparing the extracellular vesicle long-chain RNA library comprises the following steps:
[0069] Step 1: Removal of DNA from extracellular vesicle RNA
[0070] In the present invention, the extracellular vesicle RNA can be RNA extracted from cells (such as cell supernatant), tissues (including but not limited to brain tissue and adipose tissue), and various body fluids and secretions (including but not limited to serum, plasma, urine, cerebrospinal fluid, saliva, nasal secretions, alveolar lavage fluid, milk, synovial fluid, semen, uterine fluid, bile, lymph, feces, amniotic fluid, embryo culture fluid), or commercial extracellular vesicle RNA. Extracellular vesicle RNA can be extracted by conventional methods in the art, including but not limited to Trizol method, centrifugal column method, magnetic bead method, LiCl precipitation method, phenol chloroform-isopropanol precipitation method to extract RNA.
[0071] Since some DNA is usually contaminated during the extraction of extracellular vesicle RNA, it is impossible to distinguish between DNA or RNA when reverse transcription is performed using random primers, resulting in the contaminated DNA also being used as a template for subsequent reactions. Therefore, in order to remove the influence of DNA contamination, the extracted RNA is usually treated to remove DNA. Methods for removing DNA known in the art can be used to remove contaminated DNA in extracellular vesicle RNA, including but not limited to: DNase treatment.
[0072] An exemplary DNase treatment process includes: incubating RNA with DNase in a DNase buffer system at 37 degrees for 30 minutes. DNases include but are not limited to: DNase I, Turbo DNase.
[0073] After using DNA enzyme to remove the contaminating DNA in the extracellular vesicle RNA, in order to eliminate the influence of DNA enzyme, usually, those skilled in the art will often purify the RNA. However, due to the low yield of extracellular vesicle RNA, the loss caused by purifying RNA will greatly affect the amount of RNA that can be used, increasing the difficulty of subsequent RNA library preparation. In a preferred embodiment of the present invention, two strategies are used to eliminate the influence of DNA enzyme to the greatest extent, one is to select the optimal DNA enzyme concentration, and the other is to use the heat inactivation method.
[0074] To select the optimal DNA enzyme concentration, it is necessary to select a smaller DNA enzyme concentration under the condition that the DNA enzyme can significantly (about 1000 times) remove DNA contamination. Since DNA enzymes can be inactivated at high temperatures, the use of heat inactivation methods can make the DNA enzyme no longer have the activity of digesting DNA, so that it will not affect the subsequent RNA library preparation. Exemplary heat inactivation conditions can be incubation at 70-90°C for 5-20 minutes, for example: incubation at 75°C for 10 minutes.
[0075] Step 2: RNA fragmentation
[0076] In order to ensure that the RNA fragments used for high-throughput sequencing meet the length requirements of the sequencer (the optimal library length is 200-400bp, and exceeding 500bp will lead to reduced library sequencing efficiency and increased error rate), and to detect circular RNA (cirRNA) in extracellular vesicles, the RNA samples (extracellular vesicle RNA) need to be randomly interrupted, a process called RNA fragmentation.
[0077] The random fragmentation can be performed using RNA fragmentation methods known in the art, including but not limited to chemical methods and enzymatic digestion methods. Chemical methods generally use alkaline solutions or divalent positive ions such as Mg 2+The solution interrupts the RNA. An increase in the reaction temperature can reduce the effect of alkaline solutions or divalent positive ions on the RNA structure. In an embodiment of the present invention, a chemical method is used to fragment the RNA. Furthermore, the reaction buffer of the subsequent reverse transcription step is used as an RNA interruption reagent. Exemplary reverse transcription buffers include: 40-60mM (e.g., 50mM) Tris-HCl, 50-100mM (e.g., 75mM) KCl, 1-5mM (e.g., 3mM) MgCl2, the pH of the reverse transcription buffer is weakly alkaline, which can be 7.5-9.0, for example, the pH is 8.3, and RNA fragmentation can be performed at room temperature (e.g., 25°C). Other reverse transcription buffers known in the art can also be used, as long as the buffer pH is weakly alkaline and contains a certain concentration of Mg 2+ .
[0078] As shown in the examples of the present invention, the reaction buffer of the subsequent reverse transcription step is used as an RNA shearing reagent. Under high temperature incubation, RNA can be effectively sheared without introducing additional enzymes, ions or other chemical reagents, and is compatible with the subsequent reverse transcription step.
[0079] Step 3: Reverse transcription using random primers and adding 3' adapter sequences
[0080] Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is the main means of RNA reverse transcription. In the RT-PCR reaction process, usually, random primers or Oligo-dT reverse transcription primers synthesize complementary cDNA with mRNA fragments as templates under the action of reverse transcriptase. Since RNA in extracellular vesicles does not have a poly (A) tail, in the method of the present invention, random primers are used for reverse transcription.
[0081] In a preferred embodiment of the present invention, the random primer carries an Illumina sequencing adapter sequence, so that a universal sequencing sequence is added to the 5' end of the cDNA obtained after reverse transcription, facilitating subsequent amplification and sequencing of the library.
[0082] Illumina sequencing adapter sequence:
[0083] P5 linker sequence (SEQ ID NO: 1)
[0084] ACACTCTTTCCCTACACGACCGCTTCCGATCT
[0085] P7 linker sequence (SEQ ID NO: 2)
[0086] GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
[0087] Step 4: Template switching and adding 5' adapter sequence
[0088] Template switching technology, also known as the switching mechanism at the 5'end of the RNA transcript (SMART), specifically, when reverse transcription reaches the 5'end of the RNA template, the terminal transferase activity of the reverse transcriptase will add some additional nucleotides (such as 3 Cs) to the 3'end of the newly synthesized cDNA chain. These nucleotides serve as template switch oligo (TSO) anchoring sites. After base pairing between TSO (such as 3 Gs) and the additional nucleotide fragment (such as 3 Cs), the reverse transcriptase "switches" the template chain from the RNA template to TSO and continues to replicate to the 5'end of TSO. By doing this, the 5'end adapter sequence is eventually added to the end of the cDNA.
[0089] Generally speaking, after adding a TSO sequence to the end of the cDNA, the reverse transcriptase will continue to add additional bases (for example, adding 3 Cs) to the end of the cDNA-TSO sequence. These bases will continue to serve as new TSO anchoring sites, continue template switching, and add the reverse complementary sequence of TSO to the end of the existing product again. However, this reaction can be repeated many times to form multiple cDNA products with a difference of one TSO length, showing a ladder distribution. When the amount of TSO is too much or the amount of RNA input is too little, the reaction is more obvious, and a large number of invalid sequences are generated. In order to remove these invalid sequences, some modifications or modified nucleosides can be added to the 5' end of TSO, and the spatial structure of these modifications can be used to generate steric hindrance, preventing new TSO sequences from entering and pairing, thereby preventing continuous template switching reactions. The modifications include (but are not limited to): nucleoside isomers (for example: iso-A / T / C / G), fluorescent groups (for example: Cy3, Cy5, FAM, TRAM) and other groups (for example: biotin).
[0090] In a preferred embodiment of the present invention, biotin is added to the 5' end of the template switching oligonucleotide sequence for modification. The biotin label, as a molecular structure added to the 5' end, can form a certain steric hindrance, thereby preventing the new TSO molecule from pairing with the GGG generated at the end of the cDNA, preventing the continuous template switching reaction, and effectively removing the tandem products of the template switching oligonucleotide sequence.
[0091] Step 5: Pre-amplification of cDNA library
[0092] RNA library preparation methods known in the art include direct amplification method and purification-amplification method.
[0093] An exemplary direct amplification method includes: removing DNA from extracellular vesicle RNA; RNA fragmentation; reverse transcription using random primers and adding 3' adapter sequences; template switching and adding 5' adapter sequences; amplifying cDNA libraries; and quality inspection of the prepared cDNA libraries. However, when preparing RNA libraries, since random primers are used for reverse transcription, if the random primers cannot be completely removed, the residual random primers will serve as subsequent amplification primers, and the direct amplification method will produce a large number of invalid byproducts, making it impossible to obtain an effective RNA library.
[0094] An exemplary purification-amplification method includes: removing DNA from extracellular vesicle RNA; RNA fragmentation; reverse transcription using random primers and adding 3' adapter sequences; template conversion and adding 5' adapter sequences; screening cDNA libraries; amplifying cDNA libraries; quality inspection of the prepared cDNA libraries. In the purification-amplification method, since the reverse transcription product is purified twice by magnetic beads and the random primers are removed, the quality of the cDNA library can be greatly improved, but correspondingly, some low-expression RNA information will be lost due to the two purifications. In addition, since ribosomal RNA is widely present in extracellular vesicles and accounts for a relatively high proportion of all RNA, most of the products obtained by the purification-amplification method come from ribosomal RNA, and ribosomal RNA cannot be effectively removed, making it difficult to obtain library information of long-chain RNA.
[0095] Therefore, in order to solve the problems existing in the direct amplification method and the purification-amplification method, a pre-amplification step is introduced in the method of the present invention, that is, the method of "pre-amplification-purification-reamplification" is adopted, and a low cycle number of pre-amplification is performed by PCR, and the absolute number of molecules derived from the target long-chain RNA sequence cDNA is appropriately increased, and the amount of cDNA derived from the self-connection of the linker or other short RNA sequences is controlled within a certain range. In addition, the pre-amplification can also keep the cDNA derived from ribosomal RNA within a reasonable range, which is convenient for the subsequent use of Cas9-sgRNA to effectively remove these unwanted sequences. For more trace samples, due to the large number of invalid by-products, the advantages of "purification-amplification" and "pre-amplification-purification-reamplification" can be integrated, and the strategy of "purification-pre-amplification-purification-reamplification" is adopted to greatly improve the quality of the library and reduce the proportion of ribosomal RNA.
[0096] Step 6: Screening of cDNA library
[0097] A variety of methods for screening and recovering cDNA libraries can be applied to the present invention, including but not limited to: using magnetic beads to screen cDNA libraries of appropriate size, and recovering cDNA libraries of appropriate size by gel excision. These methods are all within the scope of the present invention.
[0098] The principle of using magnetic beads to screen cDNA libraries of appropriate size is that the same magnetic beads have different affinities for cDNAs of different lengths. The smaller the cDNA fragment, the weaker the affinity, and the larger the cDNA fragment, the stronger the affinity. By controlling the volume ratio of cDNA and magnetic beads and adjusting the concentration of NaCl in the system, the surface charge of cDNA can be affected, thereby affecting the affinity between cDNA and magnetic beads.
[0099] The steps of an exemplary magnetic bead screening of a cDNA library of appropriate size include: using 1.8 times the volume ratio of Beckman Ampure XP magnetic beads of the pre-amplification system to mix evenly with the pre-amplification product, standing still until the cDNA and the magnetic beads are fully combined, placing on a magnetic stand to remove the supernatant, washing twice with 80% ethanol, and adding an appropriate amount of enzyme-free water to resuspend the magnetic beads. After the DNA is dissociated from the magnetic beads, it is placed on a magnetic stand again, and the supernatant is a pure cDNA library. Using the current ratio of magnetic beads, products less than 200bp can be removed to obtain a library size between 200-500bp. The use of magnetic beads to screen and recover cDNA libraries is highly efficient, and is compatible with automated platforms to process a large number of samples, such as the Agilent Bravo and Tecan Fluent automated workstations commonly found on the market. In a preferred embodiment of the present invention, the method of the present invention can be successfully compatible with Agilent's Bravo platform.
[0100] Step 7: Use Cas9-sgRNA to remove ribosomal RNA fragments
[0101] There are a large number of ribosomal RNAs in extracellular vesicles. The byproducts derived from these RNAs greatly interfere with the preparation of the library, resulting in most of the sequencing throughput being wasted and unable to provide effective information.
[0102] Methods known in the art for eliminating rRNA include, but are not limited to: Illumina RiboZero Gold, Lexogen RiboCop, Qiagen GeneRead rRNA depletion based on magnetic beads-probes to capture and remove rRNA, NEBNext rRNA Depletion, Kapa RiboErase, Takara Ribogone based on probe-RNAse H degradation. However, the above methods are only for large RNA samples (greater than 100ng), and cannot be applied to the removal of ribosomal rRNA in trace RNA samples.
[0103] In the method of the present invention, in order to specifically remove the high-abundance fragments derived from ribosomal RNA in the library, relevant sgRNAs are designed. After these sgRNAs form a complex with the Cas9 protein, they can effectively remove the double-stranded DNA products derived from ribosomal RNA in a suitable system (such as 1X NEBuffer3.1), enrich the DNA products derived from other effective RNA sequences, and greatly improve the data output and signal-to-noise ratio.
[0104] Therefore, the present invention also provides a method for removing ribosomal RNA, the method comprising: using Cas9-sgRNA to remove ribosomal RNA in a targeted manner. In a preferred embodiment of the present invention, the sgRNA is an sgRNA designed for ribosomal RNA, and more preferably, the sequence of the sgRNA is shown in Table 2.
[0105] Step 8: Re-amplify the cDNA library
[0106] In the method of the present invention, since ribosomal RNA contamination is removed in steps 5)-7), the obtained RNA can be amplified with a high number of cycles to produce a sufficient amount of library for sequencing. In order to make full use of the sequencing space and save costs, a short, variable base sequence (index) for labeling is inserted into the connector to sequence different samples simultaneously.
[0107] Step 9: Screening of cDNA library
[0108] In the method of the present invention, the method for screening the cDNA library used in step 9) is the same as the method for screening the cDNA library used in step 6).
[0109] Step 10: Quality check of the prepared cDNA library
[0110] In order to determine the yield, quality and content of ribosomal RNA products from the library, quality inspection can be performed before sequencing the prepared cDNA library, so that the library that meets the requirements can be directly used for sequencing and analysis. The quality inspection methods include but are not limited to: determination of cDNA library concentration, detection of library size distribution and fluorescence quantitative PCR analysis.
[0111] Extracellular vesicle long RNA library and its application
[0112] The present invention provides an extracellular vesicle long-chain RNA library prepared using the preparation method described in any embodiment of the present invention.
[0113] The present invention provides the use of the extracellular vesicle long-chain RNA library described in any embodiment of the present invention in the diagnosis, prevention or treatment of a disease. The present invention also provides the use of the extracellular vesicle long-chain RNA library described in any embodiment of the present invention in the preparation of a drug for the diagnosis, prevention or treatment of a disease.
[0114] The application of the extracellular vesicle long-chain RNA library described in the present invention in the diagnosis, prevention or treatment of diseases includes but is not limited to: performing sequencing analysis or sequence comparison; performing analysis of gene structure, expression or regulation; screening or analyzing functional genes; screening or analyzing disease genes (disease-causing genes); monitoring or analyzing test tube embryo quality or sperm quality; or analyzing gene abundance.
[0115] In one or more embodiments, the diseases include (but are not limited to): tumors, preeclampsia, Parkinson's disease. For example, the extracellular vesicle long-chain RNA library of the present invention can be used to screen or analyze tumor genes, thereby performing tumor screening, prognosis and recurrence analysis, etc. In one or more embodiments, the screening or analysis of the functional genes or disease genes (pathogenic genes) includes screening or analysis in the absence of disease, early, middle, late or prognosis of the disease.
[0116] The use of the extracellular vesicle long-chain RNA library described in the present invention in the diagnosis, prevention or treatment of a disease does not include a method for diagnosing or treating a disease.
[0117] The present invention provides a method for preparing an extracellular vesicle long-chain RNA library according to the present invention, which is applied to the preparation of a high-throughput sequencing library. The present invention also provides a high-throughput sequencing kit, which is used to implement the method for preparing an extracellular vesicle long-chain RNA library according to any embodiment of the present invention or to sequence the prepared extracellular vesicle long-chain RNA library.
[0118] The main advantages of the present invention are:
[0119] (1) In view of the low yield of EV RNA, the method of the present invention integrates the template switch technology to improve the efficiency of RNA capture. Using more than 0.1 ng of extracellular vesicle RNA, nearly 15,000 gene expression information can be obtained, which has extremely high sensitivity.
[0120] (2) To address the problem of high rRNA content in EV RNA, the method of the present invention integrates Cas9-sgRNA treatment, combined with two amplifications and screening, to specifically remove the high proportion of rRNA in the long-chain RNA of extracellular vesicles, discard invalid interference information, retain valid information to the maximum extent, and increase the recovery rate of valid data.
[0121] (3) The method of the present invention uses random reverse transcription primers to synthesize cDNA, which solves the problem that the long-chain RNA of extracellular vesicles does not have a poly (A) tail and cannot be prepared using an oligo-dT-based reverse transcription method, and is reproducible.
[0122] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.
[0123] The main process of library construction is summarized as follows: (1) obtaining extracellular vesicles and their RNA; (2) DNase I treatment to remove DNA from extracellular vesicle RNA; (3) random RNA shearing; (4) reverse transcription with random primers and adding 3' adapter sequence; (5) template conversion and adding 5' adapter sequence; (6) pre-amplification of cDNA library with universal adapter primers; (7) recovery of pre-amplified cDNA library with magnetic beads; (8) targeted removal of high-abundance fragments derived from ribosomal RNA in the library by Cas9-sgRNA complex; (9) re-amplification of cDNA library with sequencing primers containing index; (10) screening of cDNA library of appropriate size with magnetic beads; (11) library quality inspection.
[0124] Adapter and primer sequences for library construction:
[0125] Illumina sequencing adapter sequence:
[0126] P5 linker sequence (SEQ ID NO: 1)
[0127] ACACTCTTTCCCTACACGACCGCTTCCGATCT
[0128] P7 linker sequence (SEQ ID NO: 2)
[0129] GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
[0130] Template switching oligonucleotide sequence (SEQ ID NO: 3)
[0131] 5'-biotin-TTTCCCTACACGACGCTCTTCCGATCTrGrG+G (rG is riboguanosine, +G is locked nucleic acid modified guanosine (LNA))
[0132] Reverse transcription primer (SEQ ID NO: 4)
[0133] 5'-GAGTTCAGACGTGTGCTCTTCCGATCTNNNNNN-3' (N is a random base, i.e. 25% A+25% G+25% C+25% T)
[0134] Pre-amplification upstream primer (SEQ ID NO: 5)
[0135] 5'-ACACTCTTTCCCTACACGACG-3'
[0136] Pre-amplification downstream primer (SEQ ID NO: 6)
[0137] 5'-GACTGGAGTTCAGACGTGTGC-3'
[0138] Re-amplify upstream primer (SEQ ID NO:7)
[0139] 5'-AATGATACGGCGACCACCGAGATCT NNNNNNNN ACACTCTTTCCCTACACGACCGCTCTTCCGATCT-3'( NNNNNNNN is a variable base sequence, used as a sequencing index)
[0140] Re-amplify downstream primer (SEQ ID NO:8)
[0141] 5'-CAAGCAGAAGACGGCATACGAGAT NNNNNNNN GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3'( NNNNNNNN is a variable base sequence, used as a sequencing index)
[0142] Example 1. Preparation of extracellular vesicles and RNA thereof
[0143] The inventors used QIAGEN exoEasy column to purify extracellular vesicles from human serum, observed their structure and size using a transmission electron microscope, and used a Malvern particle size analyzer to calculate their size distribution. Figure 1 As shown in a and 1b, the size of purified human serum extracellular vesicles ranges from 50 to 300 nanometers, mainly concentrated around 120 nanometers, and presents a three-dimensional structure with a depression in the middle.
[0144] Subsequently, the inventors used Trizol reagent to purify the extracellular vesicle RNA and used Agilent Tapestation 2200 to perform a quality check on the RNA size. Figure 1As shown in Figure c, the size of human serum extracellular vesicle RNA is between 25 and 6000 nt, and is mainly distributed between 80 and 500 nt. The above results are highly consistent with the reported extracellular vesicle structure, size and RNA size distribution.
[0145] Example 2: Removal of DNA from extracellular vesicle RNA
[0146] In order to test the appropriate DNase I concentration, the inventors synthesized 6 DNA fragments ranging from 100 to 500 nt, the sequences of which are shown in Table 1.
[0147] Table 1
[0148]
[0149] The DNA mixture was mixed according to the ratio in the table to form a DNA mixture. The DNA mixture was then mixed with the extracellular vesicle RNA prepared in Example 1 at a ratio of 1:1 to prepare a test sample ( Figure 2 a). For 1 ng of the test sample, the inventors designed multiple groups of DNA enzyme treatment without treatment, 0.11 units of DNA enzyme treatment, 0.33 units of DNA enzyme treatment and 1 unit of DNA enzyme treatment for parallel experiments. The treatment conditions were incubated at 37°C for 30 minutes. After the incubation, the DNA enzyme in the test sample was incubated at 75°C for 10 minutes for high temperature inactivation, and was directly used for fluorescent quantitative PCR detection after dilution. The optimal DNA enzyme concentration was determined by the change in DNA content. The corresponding fluorescent quantitative PCR primers are shown in Table 2.
[0150] Table 2
[0151]
[0152] like Figure 2 As shown in b, compared with the untreated control, the DNA content in the sample was significantly reduced by up to about 1000 times (10 cycles) after treatment with 0.11 units of DNA enzyme; while with 0.33 units of DNA enzyme treatment, the DNA was further digested, and even using a higher concentration of DNA enzyme could not further increase the removal effect, indicating that the current amount of DNA enzyme used has reached saturation.
[0153] Therefore, it is preferred to use 0.33 units of DNase for 1 ng of extracellular vesicle RNA at 37°C for 30 minutes.
[0154] Example 3: Extracellular vesicle RNA fragmentation
[0155] The extracellular vesicle RNA from which DNA was removed by the preferred method in Example 2 was used as the analysis object, and the fragmentation of the extracellular vesicle RNA was analyzed.
[0156] In order to determine the optimal RNA shearing conditions, the inventors tested different solution systems, including water, reverse transcription buffer (50mM Tris-HCl, 75mM KCl, pH 8.3) and reverse transcription buffer containing magnesium ions (50mM Tris-HCl, 75mM KCl, 3mM MgCl2, pH 8.3). The inventors also tested the effects of different shearing times on fragmentation, including 2 minutes, 4 minutes and 8 minutes. After analysis, the temperature condition was ideal at high temperature (84°C).
[0157] The test results under some conditions are shown in Table 3.
[0158] Table 3. Effects of different RNA shearing conditions
[0159]
[0160] As can be seen from Table 3, compared with no disruption, only using water and high temperature cannot effectively disrupt RNA; reverse transcription buffer and high temperature are more effective, but still too mild; reverse transcription buffer containing magnesium ions and high temperature can effectively disrupt RNA, and the RNA is disrupted to a reasonable size range for library construction (the range is 80-300 nt) in about 2 minutes.
[0161] Therefore, it is preferred that the RNA be incubated in a reverse transcription buffer containing magnesium ions at 84°C for 2 minutes.
[0162] Example 4: Comparison of different amplification strategies
[0163] The fragmented product of Example 3 was reverse transcribed using random primers and a 3' adapter sequence was added, followed by template switching and a 5' adapter sequence was added, and the cDNA library was amplified.
[0164] The advantage of random primers for reverse transcription is that they are not restricted by sequence and are effective for all RNA. However, random primers also have their inherent defects: if they are not removed completely, they will act as subsequent amplification primers and produce a large number of invalid byproducts. In order to compare the effects of different random primer residues on the library and select the best amplification conditions, the inventors tested three different amplification strategies ( Figure 3 ac). The specific conditions of the strategy are shown in Table 4.
[0165] Table 4. Specific methods of different amplification strategies
[0166]
[0167]
[0168] The inventors' analysis showed that the direct amplification strategy is to directly amplify the reverse transcription product, leaving a large amount of random primers; the purification-amplification strategy is to purify the reverse transcription product twice with magnetic beads to remove random primer residues as much as possible; the pre-amplification-purification-re-amplification strategy is to first amplify the reverse transcription product with a low cycle number, purify it with magnetic beads twice, and then amplify it for the second time. Since information is lost each time the magnetic beads are recovered, this method retains the RNA expression information as much as possible while removing random primer residues as much as possible.
[0169] like Figure 3 As shown in Figure d, the library generated by the direct amplification strategy is basically a byproduct with a size of 100-200bp, and the library quality is very poor; the purification-amplification strategy greatly removes the byproducts and retains the effective library of 200-500bp, but the loss of this part of the effective product is also serious; the pre-amplification-purification-reamplification strategy retains more effective products (but there are still byproducts that have not been removed).
[0170] Therefore, in subsequent experiments, the strategy was based on purification-amplification or pre-amplification-purification-reamplification.
[0171] Example 5: Primer design and comparison of two rounds of PCR
[0172] The preferred pre-amplification-purification-reamplification strategy effectively reduces information loss, but the inventors found that there are still byproducts in the library. According to the inventors' analysis, if the product obtained by pre-amplification is smaller, it can be separated and purified more cleanly. The inventors tested two different combinations of amplification primers. The method and conditions of pre-amplification are the same as those in Example 4.
[0173] Combination 1: Primers SEQ ID NOs: 5 and 6 were used for pre-amplification; primers SEQ ID NOs: 7 and 8 were used for secondary amplification.
[0174] Combination 2: primers of SEQ ID NOs: 7 and 8 were used for pre-amplification; primers of SEQ ID NOs: 27 and 28 were used for secondary amplification.
[0175] Re-amplify upstream primer 2 (SEQ ID NO: 27)
[0176] 5'-AATGATACGGCGACCACCGAGATCT-3'
[0177] Re-amplify downstream primer 2 (SEQ ID NO: 28)
[0178] 5'-CAAGCAGAAGACGGCATACGAG-3'
[0179] The results showed that the product obtained by pre-amplification of combination 1 was smaller. Figure 4As shown in b, it is very obvious that combination 1 can obtain more effective libraries with a size of 200-500 bp under the same conditions (comparison between sample 2 and sample 3; comparison between sample 5 and sample 6).
[0180] Therefore, in subsequent experiments, the amplification method of combination 1 was used.
[0181] Example 6: Selection of different template switching sequences
[0182] The above preferred amplification strategies and primer combinations can successfully construct a library, but analysis of the results shows that there are some products even when there is no RNA input, which appear as multiple single bands with fixed intervals, and are the tandem products of the template conversion oligonucleotide sequence.
[0183] To solve the above problems, the inventors added a biotin modification, i.e., 5'-biotin-TSO, to the end of the original template switching oligonucleotide sequence (SEQ ID NO: 29). The inventors constructed libraries using the original template switching oligonucleotide sequence and the template switching oligonucleotide sequence with biotin modification (SEQ ID NO: 3), respectively, and compared their effects on the quality of the libraries.
[0184] Original template switching oligonucleotide sequence (SEQ ID NO:29):
[0185] 5'-TTTCCCTACGACGCTCTTCCGATCTrGrG+G-3'
[0186] Template switching oligonucleotide sequence (SEQ ID NO: 3)
[0187] 5'-biotin-TTTCCCTACACGACGCTCTTCCGATCTrGrG+G (rG is riboguanosine, +G is locked nucleic acid modified guanosine (LNA))
[0188] like Figure 4 As shown in b, the original template switching oligonucleotide sequence produces a large number of tandem byproducts, while the modified template switching oligonucleotide sequence greatly eliminates the production of such products and produces a high-quality library.
[0189] Therefore, in subsequent experiments, template switching oligonucleotide sequences modified with biotin are preferred.
[0190] Example 7: Cas9-sgRNA complex removes ribosomal RNA contamination products
[0191] Based on the above, the present inventors used Qiagen exoEasy column to purify serum and plasma extracellular vesicles, used Trizol to purify the RNA therein, and constructed a long-chain RNA library using the above-mentioned library construction method.
[0192] The inventors' sequencing analysis results showed that the extracellular vesicle long-chain RNA library in plasma samples has a high proportion of products derived from cellular ribosomal RNA, accounting for up to 64%, and also contains some products derived from mitochondrial ribosomal RNA, accounting for about 23%, and valid data accounts for only about 13%; while in serum samples, there is a very high proportion of products derived from mitochondrial ribosomal RNA, accounting for up to 85%. This part of the data derived from ribosomal RNA greatly occupies the sequencing data, resulting in waste and loss of valid data ( Figure 6 , before treatment).
[0193] To solve the above problems, the inventors conducted in-depth analysis and research and considered a variety of solutions. As a result, they found that adding the Cas9-sgRNA complex for cutting after pre-amplification and recovery of the library construction can greatly improve this problem.
[0194] 1. Design and preparation of sgRNA targeting ribosomal RNA
[0195] The inventors designed 79 sgRNAs (as shown in Table 5) based on the ribosomal RNA sequences in extracellular vesicles. Amplification primers containing these sgRNA sequences were synthesized to obtain in vitro transcribed DNA templates ( Figure 5 a). T7 RNA polymerase was then used to synthesize the complete sgRNA using ribo NTP (rNTP) as substrate ( Figure 5 b).
[0196] Table 5. sgRNA sequence information
[0197]
[0198]
[0199]
[0200] 2. Preparation of Cas-sgRNA complex
[0201] Cas9 protein, prepared sgRNA and 1X NEBuffer 3.1 were mixed evenly and incubated at 37°C for 30 minutes to assemble the Cas9-sgRNA complex.
[0202] 3. Cas-sgRNA complex treatment
[0203] The cDNA library was pre-amplified and recovered to obtain 15 μl of pure product. About half of the product (7.2 μl) was taken with 2.8 μl of pre-assembled Cas-sgRNA complex, mixed evenly and incubated at 37°C overnight. Then 0.5 μl of 20 μg / μl Qiagen Protease was added, incubated at 50°C for 30 minutes to digest the Cas9 protein, and then incubated at 77 degrees for 20 minutes to inactivate the Protease. The treated product can be directly used for subsequent re-amplification.
[0204] The results showed that after the same library was processed, the products derived from ribosomal RNA were greatly reduced. The contaminated cellular ribosomal RNA products in plasma samples were reduced to 19%, while the contaminated mitochondrial ribosomal RNA products in serum samples were reduced to 36%. At the same time, the amount of effective data increased to about 64% and 63%, respectively.
[0205] The above results show that Cas-sgRNA treatment can effectively remove ribosomal RNA contamination in the extracellular vesicle long-chain RNA library, thereby improving the library quality and the proportion of valid data.
[0206] Example 9: Method sensitivity and repeatability evaluation
[0207] In order to evaluate the sensitivity and repeatability of the method, the inventors used purified plasma extracellular vesicle RNA, and used 100 pg, 500 pg, 1 ng and 2 ng of RNA, respectively, to construct a long-chain RNA library and sequence it using the above-mentioned optimized method. The steps include (the method not described in detail is a conventional method or using commercial reagents / kits):
[0208] (1) Obtaining extracellular vesicles and their RNA: Extraction using the method of Example 1.
[0209] (2) DNase I treatment: Preferably, 0.33 units of DNase I are used for 1 ng of extracellular vesicle RNA at 37°C for 30 minutes.
[0210] (3) Random RNA shearing: Incubate at 84°C for 2 minutes in a reverse transcription buffer containing magnesium ions.
[0211] (4) Random primer reverse transcription and addition of 3' adapter sequence: Use random primers carrying Illumina sequencing adapter sequences for reverse transcription. After reverse transcription, a universal sequencing sequence is added to the 5' end of the cDNA obtained.
[0212] (5) Template switching and adding 5' linker sequence: As in Example 6, a template switching sequence modified with biotin was used.
[0213] (6) Pre-amplify the cDNA library using universal adapter primers of SEQ ID NO: 5 and 6: amplify for 5-7 cycles using NEB Q5 HiFiHotStart DNA polymerase system.
[0214] (7) 1.8X Beckman Ampure XP magnetic beads to recover DNA library: The current ratio can remove products below 150 bp and obtain a cDNA library of about 200-500 bp.
[0215] (8) The Cas9-sgRNA complex specifically removes high-abundance fragments derived from ribosomal RNA in the library, as described in Example 7.
[0216] (9) amplifying the cDNA library again using amplification primers containing indexes of SEQ ID NOs: 7 and 8;
[0217] (10) 1X Beckman Ampure XP magnetic beads were used to recover the DNA library. The current ratio of magnetic beads can remove products below 200 bp and screen effective products of 200-500 bp.
[0218] The quality of the obtained library was tested. Figure 7 As shown, nearly 20,000 genes can be detected using 100 pg of RNA extracted from extracellular vesicles, and the information loss is less compared to higher RNA input amounts, indicating that this method has good sensitivity.
[0219] At the same time, extremely high correlation was shown between repeated samples and between samples with different RNA input amounts, indicating that this method can stably present information on gene expression and has good repeatability.
[0220] Example 10: Analysis of long-chain RNA characteristics of extracellular vesicles in serum of patients with lung cancer
[0221] In order to evaluate the performance of the method in real samples, the inventors collected 10 plasma samples from lung cancer patients from different sources. Extracellular vesicles were purified using the Qiagen exoEasy column, and vesicle RNA was purified using Trizol. Subsequently, a long-chain RNA library was constructed using the method of Example 9 and sequenced and analyzed.
[0222] like Figure 8As shown, the proportion of data derived from ribosomal RNA in the extracellular vesicle long-chain RNA libraries of 10 plasma samples is relatively low, all below 6%, indicating that the method of the present invention can effectively control the contamination of ribosomal RNA. More than 20,000 genes can be detected in all samples, and there is a good correlation between different samples, but there is also heterogeneity. Analysis of the top 10,000 genes expressed shows that the gene expression trends in different samples are similar overall, but there are many differences in the specific details, which reflects the differences between samples. The above results collectively prove that this method can be used to analyze the long-chain RNA information of plasma extracellular vesicles, and performs well in real samples.
[0223] Table 6 lists 10 of these genes and their characteristics.
[0224] Table 6
[0225]
[0226]
[0227] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.
[0228] Sequence information
[0229] Cell ribosomal RNA sequence (SEQ ID NO: 109)
[0230]
[0317] CCCTCGCCAAATCGACCTCGTACGACTCTTAGCGGTGGATCACTCGGCTCGTGCGTCGATGAAGAACGCA
[0318] GCTAGCTGCGAGAATTAATGTGAATTGCAGGACACATTGATCATCGACACTTCGAACGCACTTGCGGCCC
[0319] CGGGTTCCTCCCGGGGCTACGCCTGTCTGAGCGTCGCTTGCCGATCAATCGCCCCCGGGGGTGCCTCCGG
[0320] GCTCCTCGGGGTGCGCGGCTGGGGGTTCCCTCGCAGGGCCCGCCGGGGGCCCTCCGTCCCCCTAAGCGCA
[0321] GACCCGGCGGCGTCCGCCCTCCTCTTGCCGCCGCGCCCGCCCCTTCCCCCTCCCCCCGCGGGCCCTGCGTG
[0322] GTCACGCGTCGGGTGGCGGGGGGGAGAGGGGGGCGCGCCCGGCTGAGAGAGACGGGGAGGGCGGCGCC
[0323] GCCGCCGCCCGCGAAGACGGAGAGGGAAAGAGAGAGCCGGCTCGGGCCGAGTTCCCGTGGCCGCCGCCT
[0324] GCGGTCCGGGTTCCTCCCTCGGGGGGCTCCCTCGCGCCGCGCGCGGCTCGGGGTTCGGGGTTCGTCGGCC
[0325] CCGGCCGGGTGGAAGGTCCCGTGCCCGTCGTCGTCGTCGTCGTCGCGCGTCGTCGGCGGTGGGGGCGTGT
[0326] TGCGTGCGGTGTGGTGGTGGGGGAGGAGGAAGGCGGGTCCGGAAGGGGAAGGGTGCCGGCGGGGAGAG
[0327] AGGGTCGGGGGAGCGCGTCCCGGTCGCCGCGGTTCGCCGCCCGCCCCCGGTGGCGGCCCGGCGTCCGGCC
[0328] GACCGCCGCTCCCGCGCCCCTCCTCCTCCCCGCCGCCCCTCCTCCGAGGCCCCGCCCGTCCTCCTCGCCCT
[0329] CCCCGCGCGTACGCGCGCCCGCCCGCCCGGCTCGCCTCGCGGCGCGTCGGCCGGGGCCGGGAGCCCGCCC
[0330] CGCGGCCCGCCCGGCCGCGCCCGTGGCCGCGGCGCCGGGGTTCGCGTGTCCCCGGCGGCGACCCGCGGGA
[0331] CGCCGCGGTGTCGTCCGCCGTCGCGCGCCCGCCTCCGGCTCGCGGCCGCGCCGCGCCGCGCCGGGGCCCC
[0332] GTCCCGAGCTTCCGCGTCGGGGCGGGGCGGCTCCGCCGCCGCGTCCTCGGACCCGTCCCCCCGACCTCCG
[0333] CGGGGGAGACGGGTCGGGGCGTGCGGCGCCCGTCCCGCCCCCGGCCCGTGCCCCTCCCTCCGGTCGTCCC
[0334] GCTCCGGCGGGGCGGCGCGGGGGTGCCGCCGGCCGCGCGCTCTCTCTCCCGTCGCCTCTCCCCCTCGCCG
[0335] GGCCCGTCTCCCGACGGAGCGTCGGGCGGGCGGTCGGGCCGGCGCGATTCCGTCCGTCCGTCCGCCGAGC
[0336] GGCCCGTCCCCCTCCGAGACGCGACCTCAGATCAGACGTGGCGACCCGCTGAATTTAAGCATATTAGTCA
[0337] GCGGAGGAGAAGAAACTAACCAGGATTCCCTCAGTAACGGCGAGTGAACAGGGAAGAGCCCAGCGCCGA
[0338] ATCCCCGCCCCGCGGCGGGGCGCGGGACATGTGGCGTACGGAAGACCCGCTCCCCGGCGCCGCTCGTGGG
[0339] GGGCCCAAGTCCTTCTGATCGAGGCCCAGCCCGTGGACGGTGTGAGGCCGGTAGCGGCCCCCGGCGCGCC
[0340] GGGCCCGGGTCTTCCCGGAGTCGGGTTGCTTGGGAATGCAGCCCAAAGCGGGTGGTAAACTCCATCTAAG
[0341] GCTAAATACCGGCACGAGACCGATAGTCAACAAGTACCGTAAGGGAAAGTTGAAAAGAACTTTGAAGAG
[0342] AGAGTTCAAGAGGGCGTGAAACCGTTAAGAGGTAAACGGGTGGGGTCCGCGCAGTCCGCCCGGAGGATT
[0343] CAACCCGGCGGCGGGTCCGGCCGTGTCGGCGGCCCGGCGGATCTTTCCCGCCCCCCGTTCCTCCCGACCC
[0344] CTCCACCCGCCCTCCCTTCCCCCGCCGCCCCTCCTCCTCCTCCCCGGAGGGGGCGGGCTCCGGCGGGTGCG
[0345] GGGGTGGGCGGGCGGGGCCGGGGGTGGGGTCGGCGGGGGACCGTCCCCCGACCGGCGACCGGCCGCCGC
[0346] CGGGCGCATTTCCACCGCGGCGGTGCGCCGCGACCGGCTCCGGGACGGCTGGGAAGGCCCGGCGGGGAA
[0347] GGTGGCTCGGGGGGCCCCGTCCGTCCGTCCGTCCGTCCTCCTCCTCCCCCGTCTCCGCCCCCCGGCCCCGC
[0348] GTCCTCCCTCGGGAGGGCGCGCGGGTCGGGGCGGCGGCGGCGGCGGCGGTGGCGGCGGCGGCGGCGGCG
[0349] GCGGGACCGAAACCCCCCCCGAGTGTTACAGCCCCCCCGGCAGCAGCACTCGCCGAATCCCGGGGCCGA
[0350] GGGAGCGAGACCCGTCGCCGCGCTCTCCCCCCTCCCGGCGCCCACCCCCGCGGGGAATCCCCCGCGAGGG
[0351] GGGTCTCCCCCGCGGGGGCGCGCCGGCGTCTCCTCGTGGGGGGGCCGGGCCACCCCTCCCACGGCGCGAC
[0352] CGCTCTCCCACCCCTCCTCCCCGCGCCCCCGCCCCGGCGACGGGGGGGGTGCCGCGCGCGGGTCGGGGGG
[0353] CGGGGCGGACTGTCCCCAGTGCGCCCCGGGCGGGTCGCGCCGTCGGGCCCGGGGGAGGTTCTCTCGGGGC
[0354] CACGCGCGCGTCCCCCGAAGAGGGGGACGGCGGAGCGAGCGCACGGGGTCGGCGGCGACGTCGGCTACC
[0355] CACCCGACCCGTCTTGAAACACGGACCAAGGAGTCTAACACGTGCGCGAGTCGGGGGCTCGCACGAAAG
[0356] CCGCCGTGGCGCAATGAAGGTGAAGGCCGGCGCGCTCGCCGGCCGAGGTGGGATCCCGAGGCCTCTCCA
[0357] GTCCGCCGAGGGCGCACCACCGGCCCGTCTCGCCCGCCGCGCCGGGGAGGTGGAGCACGAGCGCACGTG
[0358] TTAGGACCCGAAAGATGGTGAACTATGCCTGGGCAGGGCGAAGCCAGAGGAAACTCTGGTGGAGGTCCG
[0359] TAGCGGTCCTGACGTGCAAATCGGTCGTCCGACCTGGGTATAGGGGCGAAAGACTAATCGAACCATCTAG
[0360] TAGCTGGTTCCCTCCGAAGTTTCCCTCAGGATAGCTGGCGCTCTCGCAGACCCGACGCACCCCCGCCACGC
[0361] AGTTTTATCCGGTAAAGCGAATGATTAGAGGTCTTGGGGCCGAAACGATCTCAACCTATTCTCAAACTTTA
[0362] AATGGGTAAGAAGCCCGGCTCGCTGGCGTGGAGCCGGGCGTGGAATGCGAGTGCCTAGTGGGCCACTTTT
[0363] GGTAAGCAGAACTGGCGCTGCGGGATGAACCGAACGCCGGGTTAAGGCGCCCGATGCCGACGCTCATCA
[0364] GACCCCAGAAAAGGTGTTGGTTGATATAGACAGCAGGACGGTGGCCATGGAAGTCGGAATCCGCTAAGG
[0365] AGTGTGTAACAACTCACCTGCCGAATCAACTAGCCCTGAAAATGGATGGCGCTGGAGCGTCGGGCCCATA
[0366] CCCGGCCGTCGCCGGCAGTCGAGAGTGGACGGGAGCGGCGGGGGCGGCGCGCGCGCGCGCGCGTGTGGT
[0367] GTGCGTCGGAGGGCGGCGGCGGCGGCGGCGGGGGTGTGGGGTCCTTCCCCGCCCCCCCCCCCACGC
[0368] CTCCTCCCCTCCTCCCGCCCACGCCCCGCTCCCCGCCCCGGAGCCCCGCGGACGCTACGCCGCGACGAGT
[0369] AGGAGGGCCGCTGCGGTGAGCCTTGAAGCCTAGGGCGCGGGCCCGGGTGGAGCCCGCGCAGGTGCAGAT
[0370] CTTGGTGGTAGTAGCAAATATTCAAACGAGAACTTTGAAGGCCGAAGTGGAGAAGGGTTCCATGTGAACA
[0371] GCAGTTGAACATGGGTCAGTCGGTCCTGAGAGATGGGCGAGCGCCGTTCCGAAGGGACGGCGATGGCC
[0372] TCCGTTGCCCTCGGCCGATCGAAAGGGAGTCGGGTTCAGATCCCCCGAATCCGGAGTGGCGGAGATGGCG
[0373] CCGCGAGGCGTCCAGTGCGGTAACGCGACCGACCGATCCCGGGAGAAGCCGGCGGGAGCCCCGGGGAGAGTTCT
[0374] CTTTTCTTGTGAAGGGCAGGGCGCCCTGGAATGGGTTCGCCCCGAGAGAGGGCCCGTGCCTTGGAAAG
[0375] CGTCGCGGTTCCGGCGGCGTCCGGTGAGCTTCCGCTGGCCCTTGAAATCCGGGGGAGAGGGTGTAAATC
[0376] TCGCGCCGGCCGTACCCATATCCGCAGCAGGTCTCCAAGGTGAACAGCCTCTGGCATGTTGGAACAATG
[0377] TAGGTAAGGGAAGTCGGCAAGCCGGATCCGTAACTTCGGGATAAGGATTGGCTCTAAGGGCTGGGTCGGT
[0378] CGGGCTGGGGCGCGAAGCGGGGCTGGGCGCGCGCCGCGGCTGGACGAGGCGCCGCCGCCCCCCCCACGC
[0379] CCGGGGCACCCCCCTCGCGGCCCTCCCCCGCCCCACCCCGCGCGCGCCGCTCGCTCCCTCCCCGCCCCGCG
[0380] CCCTCTCTCTCTCTCTCTCCCCCGCTCCCCGTCCTCCCCCCTCCCCGGGGGAGCGCCGCGTGGGGGCGGCG
[0381] GCGGGGGGAGAAGGGTCGGGGCGGCAGGGGCCGGCGGCGGCCCGCCGCGGGGCCCCGGCGGCGGGGGC
[0382] ACGGTCCCCCGCGAGGGGGGCCCGGGCACCCGGGGGGCCGGCGGCGGCGGCGACTCTGGACGCGAGCCG
[0383] GGCCCTTCCCGTGGATCGCCCCAGCTGCGGCGGGCGTCGCGGCCGCCCCCGGGGAGCCCGGCGGGCGCCG
[0384] GCGCGCCCCCCCCCCCACCCCACGTCTCGTCGCGCGCGCGTCCGCTGGGGGCGGGGAGCGGTCGGGCGGC
[0385] GGCGGTCGGCGGGCGGCGGGGCGGGGCGGTTCGTCCCCCCGCCCTACCCCCCCGGCCCCGTCCGCCCCCC
[0386] GTTCCCCCCTCCTCCTCGGCGCGCGGCGGCGGCGGCGGCAGGCGGCGGAGGGGCCGCGGGCCGGTCCCCC
[0387] CCGCCGGGTCCGCCCCCGGGGCCGCGGTTCCGCGCGGCGCCTCGCCTCGGCCGGCGCCTAGCAGCCGACT
[0388] TAGAACTGGTGCGGACCAGGGGAATCCGACTGTTTAATTAAAACAAAGCATCGCGAAGGCCCGCGGCGG
[0389] GTGTTGACGCGATGTGATTTCTGCCCAGTGCTCTGAATGTCAAAGTGAAGAAATTCAATGAAGCGCGGGT
[0390] AAACGGCGGGAGTAACTATGACTCTCTTAAGGTAGCCAAATGCCTCGTCATCTAATTAGTGACGCGCATG
[0391] AATGGATGAACGAGATTCCCACTGTCCCTACCTACTATCCAGCGAAACCACAGCCAAGGGAACGGGCTTG
[0392] GCGGAATCAGCGGGGAAAGAAGACCCTGTTGAGCTTGACTCTAGTCTGGCACGGTGAAGAGACATGAGA
[0393] GGTGTAGAATAAGTGGGAGGCCCCCGGCGCCCCCCCGGTGTCCCCGCGAGGGGCCCGGGGCGGGGTCCG
[0394] CCGGCCCTGCGGGCCGCCGGTGAAATACCACTACTCTGATCGTTTTTTCACTGACCCGGTGAGGCGGGGG
[0395] GGCGAGCCCCGAGGGGCTCTCGCTTCTGGCGCCAAGCGCCCGGCCGCGCGCCGGCCGGGCGCGACCCGCT
[0396] CCGGGGACAGTGCCAGGTGGGGAGTTTGACTGGGGCGGTACACCTGTCAAACGGTAACGCAGGTGTCCTA
[0397] AGGCGAGCTCAGGGAGGACAGAAACCTCCCGTGGAGCAGAAGGGCAAAAGCTCGCTTGATCTTGATTTTC
[0398] AGTACGAATACAGACCGTGAAAGCGGGGCCTCACGATCCTTCTGACCTTTTGGGTTTTAAGCAGGAGGTG
[0399] TCAGAAAAGTTACCACAGGGATAACTGGCTTGTGGCGGCCAAGCGTTCATAGCGACGTCGCTTTTTGATC
[0400] CTTCGATGTCGGCTCTTCCTATCATTGTGAAGCAGAATTCACCAAGCGTTGGATTGTTCACCCACTAATAG
[0401] GGAACGTGAGCTGGGTTTAGACCGTCGTGAGACAGGTTAGTTTTACCCTACTGATGATGTGTTGTTGCCAT
[0402] GGTAATCCTGCTCAGTACGAGAGGAACCGCAGGTTCAGACATTTGGTGTATGTGCTTGGCTGAGGAGCCA
[0403] ATGGGGCGAAGCTACCATCTGTGGGATTATGACTGAACGCCTCTAAGTCAGAATCCCGCCCAGGCGGAAC
[0404] GATACGGCAGCGCCGCGGAGCCTCGGTTGGCCTCGGATAGCCGGTCCCCCGCCTGTCCCCGCCGGCGGGC
[0405] CGCCCCCCCCCTCCACGCGCCCCGCGCGCGCGGGAGGGCGCGTGCCCCGCCGCGCGCCGGGACCGGGGTC
[0406] CGGTGCGGAGTGCCCTTCGTCCTGGGAAACGGGGCGCGGCCGGAGAGGCGGCCGCCCCCTCGCCCGTCAC
[0407] GCACCGCACGTTCGTGGGGAACCTGGCGCTAAACCATTCGTAGACGACCTGCTTCTGGGTCGGGGTTTCG
[0408] TACGTAGCAGAGCAGCTCCCTCGCTGCGATCTATTGAAAGTCAGCCCTCGACACAAGGGTTTGTCCGCGC
[0409] GCGCGCGCGCGCGCGCGTGCGGGGGGCCCGGCGGGGCGTGCGCGTCCGGCGCCGTCCGTCCTTCCGTTCG
[0410] TCTTCCTCCCTCCCGGCCTCTCCCGCCGACCGCGGGCGTGGTGGTGGGGGTGTGGGGGGGAGGGCGCGCG
[0411] ACCCCGGTCGGCGCGCCCCGCTTCTTCGGTTCCCGCCTCCTCCCCGTTCACCGCCGGGGCGGCTCGTCCGC
[0412] TCCGGGCCGGGACGGGGTCCGGGGAGCGTGGTTTGGGAGCCGCGGAGGCGGCCGCGCCGAGCCGGGCCC
[0413] GTGGCCCGCCGGTCCCCGTCCCGGGGGTTGGCCGCGCGGGCCCCGGTGGGGCGGCCACCCGGGGTCCCGG
[0414] CCCTCGCGNNNNNNNATAGGTTTGGTCCTAGCCTTTCTATTAGCTCTTAGTAAGATTACACATGCAAGCAT
[0415] CCCCGTTCCAGTGAGTTCACCCTCTAAATCACCACGATCAAAAGGAACAAGCATCAAGCACGCAGCAATG
[0416] CAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACGA
[0417] AAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACCGCGGTCACACGATTAA
[0418] CCCAAGTCAATAGAAGCCGGCGTAAAGAGTGTTTTAGATCACCCCCTCCCCAATAAAGCTAAAACTCACC
[0419] TGAGTTGTAAAAAACTCCAGTTGACACAAAATAGACTACGAAAGTGGCTTTAACATATCTGAACACACAA
[0420] TAGCTAAGACCCAAACTGGGATTAGATACCCCACTATGCTTAGCCCTAAACCTCAACAGTTAAATCAACA
[0421] AAACTGCTCGCCAGAACACTACGAGCCACAGCTTAAAACTCAAAGGACCTGGCGGTGCTTCATATCCCTC
[0422] TAGAGGAGCCTGTTCTGTAATCGATAAACCCCGATCAACCTCACCACCTCTTGCTCAGCCTATATACCGCC
[0423] ATCTTCAGCAAACCCTGATGAAGGCTACAAAGTAAGCGCAAGTACCCACGTAAAGACGTTAGGTCAAGGT
[0424] GTAGCCCATGAGGTGGCAAGAAATGGGCTACATTTTCTACCCCAGAAAACTACGATAGCCCTTATGAAAC
[0425] TTAAGGGTCGAAGGTGGATTTAGCAGTAAACTAAGAGTAGAGTGCTTAGTTGAACAGGGCCCTGAAGCGC
[0426] GTACACACCGCCCGTCACCCTCCTCAAGTATACTTCAAAGGACATTTAACTAAAACCCCTACGCATTTATA
[0427] TAGAGGAGACAAGTCGTAACATGGTAAGTGTACTGGAAAGTGCACTTGGACGAAC
[0428] Mitochondrial ribosomal RNA sequence (SEQ ID NO: 110)
Claims
1. A method for preparing an extracellular vesicle long-chain RNA library, comprising: i) providing extracellular vesicle RNA, performing RNA fragmentation, and obtaining fragmentation products; ii) reverse transcription using random primers to obtain reverse transcription products; iii) performing a first amplification on the reverse transcription product and purifying it to obtain cDNA; iv) Removal of ribosomal RNA (rRNA) using sgRNA targeting ribosomal RNA (rRNA) by CRISPR / Cas method; v) Perform a second amplification and purify the cDNA to obtain an extracellular vesicle long-chain RNA library.
2. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: The extracellular vesicle RNA is RNA extracted from extracellular vesicles; preferably, the extracellular vesicles are derived from cells, tissues and body fluids; more preferably, the extracellular vesicles are derived from cell supernatant, serum, plasma, urine, cerebrospinal fluid, saliva, nasal secretions, alveolar lavage fluid, milk, synovial fluid, semen, uterine fluid, bile, lymph, feces, adipose tissue, brain tissue, amniotic fluid, and embryo culture fluid.
3. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: The step i) further comprises: removing DNA from the extracellular vesicle RNA; Preferably, the removal of DNA in extracellular vesicle RNA includes: removing DNA in extracellular vesicle RNA by DNase treatment; more preferably, the DNase includes: DNaseI, Turbo DNase; even more preferably, 0.25-0.50 units of DNase are used for 1 ng of extracellular vesicle RNA.
4. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: In the step i), the RNA fragmentation includes: RNA shearing treatment by chemical method and / or enzyme digestion method; preferably, after RNA fragmentation, the RNA fragment size is 80 to 300 nt; more preferably, RNA is fragmented in a reverse transcription buffer containing magnesium ions.
5. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: The step ii) comprises: reverse transcription using random primers and adding a 3' adapter sequence, and template switching and adding a 5' adapter sequence; Preferably, the random primer carries an Illumina sequencing adapter sequence that is compatible with Illumina sequencing adapter sequence, and more preferably, the Illumina sequencing adapter sequence is as shown in SEQ ID NO: 1 or 2; and / or, Preferably, the template switching is performed by using a template switching oligonucleotide, so that a 5' adapter sequence is added to the end of the cDNA; more preferably, the template switching oligonucleotide sequence is as shown in SEQ ID NO: 3 or 29.
6. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: In the step iv), the sgRNA includes an sgRNA selected from the nucleotide sequences shown in SEQ ID NOs: 30 to 108.
7. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: The purification method described in step iii) and step v) is purification using magnetic beads; preferably, the cDNA fragment obtained after purification using magnetic beads has a size of 200-500 bp.
8. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: The amplification in step iii) and step v) is PCR amplification; preferably, the PCR amplification in step iii) is a PCR amplification with a low cycle number (preferably 5 to 7 cycles), and the PCR amplification in step v) is a PCR amplification with a high cycle number (preferably 7 to 10 cycles).
9. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: In step iii), during the first amplification, amplification is performed using primers shown in SEQ ID NOs: 5 and 6, or SEQ ID NOs: 7 and 8, and / or, in step v), during the second amplification, amplification is performed using primers shown in SEQ ID NOs: 7 and 8, or SEQ ID NOs: 27 and 28.
10. The method for preparing an extracellular vesicle long-chain RNA library according to claim 1, characterized in that: The preparation method further comprises: performing quality inspection and / or sequencing on the obtained extracellular vesicle long-chain RNA library; Preferably, the quality inspection includes: determination of cDNA library concentration, detection of library size distribution and / or fluorescence quantitative PCR analysis. 11 . An extracellular vesicle long-chain RNA library, prepared by the method for preparing an extracellular vesicle long-chain RNA library according to any one of claims 1 to 10.
12. Use of the method for preparing an extracellular vesicle long-chain RNA library according to any one of claims 1 to 10, comprising: Perform sequencing analysis or sequence comparison; Conduct analysis of gene structure, expression or regulation; Screening or analysis of functional genes; Screening or analyzing disease genes; Monitoring or analyzing IVF embryo quality or sperm quality; or Analyze gene abundance; Preferably, the diseases include: tumor, preeclampsia, Parkinson's disease; Preferably, the screening or analysis includes screening or analysis in the absence of disease, early stage, middle stage, late stage or prognosis of disease.
13. A method for removing ribosomal RNA from a cDNA product of extracellular vesicle RNA, comprising: The ribosomal RNA is removed by CRISPR / Cas method using sgRNA targeting ribosomal RNA; preferably, the sgRNA includes an sgRNA selected from the nucleotide sequence shown in SEQ ID NO: 30 to 108.
